Enhanced Cyclooxygenase-2 Expression in Sporadic and Familial Adenomatous Polyposis of the Human Colon

References

• Needleman P, Isakson PC. The discovery and function of COX-2. J Rheumatol 1997;24:6–7.
   PubMedGoogle Scholar
• Ben-Av P, Crofford LJ, Wilder RL, Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett 1995;372: 83–7.
   Google Scholar
• Goodwin JS, Ceuppens J. Regulation of the immune response by prostaglandins. J Clin Immunol 1983;3:295–314.
   PubMed Web of Science ®Google Scholar
• Reddy BS, Maruyama H, Kelloff G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug during different stages of rat colon tumor development. Cancer Res 1987;47:5340–6.
   Google Scholar
• Giovanucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333:609–14.
   PubMed Web of Science ®Google Scholar
• Funkhouser EM, Sharp GB. Aspirin and reduced risk of esophageal cancer. Cancer 95;76: 1116–9.
   Google Scholar
• DuBois RN, Award J, Morrow J, Roberts LJ, Bishop PR. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-alpha and phorbol ester. J Clin Invest 1994;93:493–98.
   Google Scholar
• Thun MJ, Namboodiri MM, Heath CW. Aspirin use and reduced risk to colon cancer. N Engl J Med 1991;325:1593–6.
   Google Scholar
• Boolbol SK, Dannenberg AJ, Chadburn A, Martucci C, Guo X, Ramonetti JT, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996;56:2556–60.
   PubMed Web of Science ®Google Scholar
• Giardiello FM, Hamilton SR, Krush AJ, Piantodosi S, Hylind LM, Celano P, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1212–6.
   Google Scholar
• Barnes CJ, Lee M. Chemo-prevention of spontaneous intestinal adenomas and the adenomatous polyposis coli in Min model with aspirin. Gastroenterology 1998;114:873–7.
   PubMed Web of Science ®Google Scholar
• Giovannucci E. The prevention of colorectal cancer by aspirin use. Biomed Pharmacother 1999;53:303–8.
   PubMed Web of Science ®Google Scholar
• Pentland AP, Scoggins JW, Scott CA, Khan KM, Han R. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis 1999;20: 1939–44.
   Google Scholar
• Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998;58:409–12.
   PubMed Web of Science ®Google Scholar
• Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle, SL, Woerner BM, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306–11.
   PubMed Web of Science ®Google Scholar
• Wilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett’s esophagus and associated angiocarcinomas. Cancer Res 1998;58:2929–34.
   PubMed Web of Science ®Google Scholar
• Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, et al. Increased expression of cyclooxygenase-2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58:3761–4.
   PubMed Web of Science ®Google Scholar
• Buckman SY, Gresham A, Hale P, Hruza G, Anast J, Masferrer J, et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998;19:723–9.
   PubMed Web of Science ®Google Scholar
• Remmele W, Schicketanz K-H. Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Path Res Pract 1993;8:227–45.
   Google Scholar
• Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995;55:3785–9.
   PubMed Web of Science ®Google Scholar
• Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Upregulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterol 1994;107:1183–8.
   PubMed Web of Science ®Google Scholar
• Sheehan RE, Wells AU, Milne DG, Hansell DM. Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities. J Comput Assist Tomogr 2000;24:259–61.
   PubMedGoogle Scholar
• Hull MA, Booth JK, Tisbury A, Scott N, Bonifer C, Markham AF, et al. Cyclooxygenase-2 is upregulated and localized to macrophages in the intestine of Min mice. Br J Cancer 1999;79: 1399–405.
   PubMed Web of Science ®Google Scholar
• Williams CS, Luongo C, Radhika AA, Zhang T, Lamps LW, Nanney LB, et al. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 1996;111:1134–40.
   PubMed Web of Science ®Google Scholar
• Nakajima T, Hamanaka K, Fukuda T, Kahiwabara K, Sano T. Why is cyclooxygenase-2 expressed in neuroendocrine cells of the human alimentary tract? Pathol Int 1997;47: 889–991.
   Google Scholar
• Robertson RP. Dominance of cyclooxygenase-2 in the regulation of pancreatic islet prostaglandin synthesis. Diabetes 1998; 47:1379–483.
   PubMed Web of Science ®Google Scholar
• Jacoby RF, Cole CE, Seibert K, Kelloff G, Lubett RA. The specific cyclooxygenase-2 inhibitor, celecoxib, causes adenoma regression in the APC mutant Min mouse model. Am Assoc Cancer Res Mtng 1997; Late Breaking Session.
   Google Scholar
• Sawaoka H, Kawano S, Tsuji S, Tsujii M, Murata H, Hori M. Effect of NSAIDs on proliferation of gastric cancer cells in vitro: possible implication of cyclooxygenase-2 in cancer development. J Clin Gastroenterol 1999;27:S47–52.
   Google Scholar
• Tsujii M, Duboise RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandinendoperoxide synthase-2. Cell 1995;83:495–501.
   Google Scholar
• Seed MP. Angiogenesis inhibition as a drug target for disease: an update. Exp Opin Invest Drugs 1996;5:1717–37.
   Google Scholar
• Form DM, Auerbach R. PGE2 and angiogenesis. Proc Soc Exp Biol Med 1983;172:214–8.
   PubMed Web of Science ®Google Scholar
• Marnett L. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992;52:5575–60.
   PubMed Web of Science ®Google Scholar
• Steinbach G, Lynch PM, Phillips RKS, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946–52.
   PubMed Web of Science ®Google Scholar
• Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998;58:409–12.
   PubMed Web of Science ®Google Scholar
• Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000;60:293–7.
   PubMed Web of Science ®Google Scholar